GLP-1 therapies influence pathways tied to addiction and reward, according to the Endocrine Society A randomized clinical trial published in JAMA Psychiatry found semaglutide reduced alcohol cravings and consumption Users commonly report: Reduced desire to drink Feeling full faster when drinking Less reward from alcohol The data: early, but directionally consistent While long-term industry sales data is still developing, the early signals from clinical studies, observational research, and population polling all point in the same direction: GLP-1 use is associated with lower alcohol consumption for at least some users
doi: 10.1038/s41423-024-01232-z 77 HaoZ-NTanX-PZhangQLiJXiaRMaZ
He noted that exposed and non-exposed patient groups were not adequately stratified by baseline AMD severity, potentially biasing the findings
BPC-157 has been found to be safe for treating inflammatory bowel disease, ligament wounds, and tendonto-bone injuries
"There is clearly a lot of potential for weight loss drugs which are still very new medications to have wide-ranging benefits for patients, so it's good to see research being undertaken to explore these
Get Started Today As the demand for GLP-1 medications continues to grow, now is the time to explore how a direct-to-consumer prescription program can enhance your service offerings and meet the evolving needs of your patients